rade $501 $441 Other 2,426 2,925 Advanced payment from customers 184 174 Deferred revenues 10 10 Convertible loan 6,461 Total current liabilities 9,582 3,550 Long-term liabilities: Liability for employees rights upon retirement 451 354 Convertible loan 5,018 Contingently redeemable warrants 1,410 1,706 Total long-term liabilities 1,861 7,078 Total liabilities 11,443 10,628 Equity: Common stock, par value $0.0001 per share; 125,000,000 shares authorized; 18,026,680 and 17,040,040 shares issued and outstanding at December 31, 2012 and June 30, 2012. 2 2 Additional paid-in capital 53,349 49,101 Accumulated deficit (53,147) (43,722) Total equity 204 5,386 Total liabilities and equity $11,597 $16,014
(1) All 2012 financial information is derived from the Company's 2012 unaudited financial statements and all 2011 financial information is derived from the Company's 2011 unaudited financial statements, as disclosed in the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission.
(2) All December 31, 2012 financial information is derived from the Company's 2012 unaudited financial statements and all June 30, 2012 financial information is derived from the Company's 2012 audited financial statements, as disclosed in the Company's Transition Report on Form 10-KT, filed with the Securities and Exchange Commission.
About Stenting and MGuard™ EPS™
Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.
In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.
The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and tPage: 1 2 3 4 5 6 7 8 9 Related medicine technology :1
. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting2
. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology3
. InspireMD Reports Results For Period Ending Sept. 30, 20124
. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients5
. InspireMD to Present at Harvard Investors Group on June 27 in New York6
. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York7
. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial8
. InspireMD Announces First Quarter 2012 Financial Results9
. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com10
. Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 201211
. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow